Evidence map›Paper›PMID 27695075›Full record

ArticlePloS one2016

Risk Factors for Poor Adherence to Betaferon® Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome.

Łukasz Jernas, Jacek Wencel, Andrzej Wiak, Marek Bieniek, Halina Bartosik-Psujek

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Impact of Adherence with Disease-Modifying Therapies on All-Cause Mortality Rates Among Veterans with Multiple Sclerosis.Medical science monitor : international medical journal of experimental and clinical research · 2022
    Article
  2. Observational
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Łukasz JernasDepartment of Neurology, Poznań University of Medical Sciences, Poznań, Poland.
Jacek WencelDepartment of Neurolofy, "L. Bierkowski" Ministry of Internal Affairs and Administration Health Care Centre in Poznan, Poznań, Poland.
Andrzej WiakDepartment of Neurology, 4th Military Clinical Hospital in Wrocław, Wrocław, Poland.
Marek BieniekBayer Sp. z o.o, Pharmaceuticals, Medical Department, Warsaw, Poland.
Halina Bartosik-PsujekFaculty of Medicine. University of Rzeszow, Rzeszów, Poland.
Poznan University of Medical Sciences · PLRzeszów University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAdherence to treatment, including early treatment discontinuation, in patients with multiple sclerosis or clinically isolated syndrome can be affected by: treatment tolerability, route of drug administration, patient age, disease duration, comorbidities, medical care, and support from their caregivers.

aimThis study aimed to identify the risk factors for poor adherence to Betaferon® treatment, including early discontinuation and omitting doses. MATERIALS AND

methods852 adult patients treated with Betaferon participated in this 24-month study. All patients were interviewed using the Risk of Drop-out Questionnaire, the Center for Epidemiologic Studies Depression Scale and the Kurtzke Expanded Disability Status Scale.

resultsPatients who stopped therapy were younger (p = 0.003) had a higher mean EDSS score (p = 0.022), higher mean number of relapses (p = 0.017), and reported more often fear of injection (p = 0.027) and adverse events (p = 0.007) than those who did not stop treatment. Comparing patients who stopped therapy in the first and the second year, patients who stopped therapy in the first year of treatment more frequently reported flu-like symptoms and fever, and those who stopped therapy in the second year reported-ineffectiveness of treatment and disease progression. Multivariable logistic regression models confirmed that young age, short disease duration, advanced and progressing disease, and poor Betaferon tolerability were related to premature treatment discontinuation. The risk of omitting a dose during therapy was increased in patients who were working or studying, who had more advanced disease or more adverse events, and in patients who received less support from their caregivers.

conclusionsSeveral reasons may lead to problems with adherence to Betaferon treatment. Patients at higher risk of discontinuing treatment need to be identified early to make caregivers' support available to them.

Indexed as

Drug MonitoringAdjuvants, ImmunologicAdultDepressionDisease ProgressionHumansInterferon beta-1bLogistic ModelsMaleMultiple Sclerosis, Relapsing-RemittingRisk FactorsSurveys and QuestionnairesTreatment OutcomeAdjuvants, ImmunologicInterferon beta-1b

Identifiers

PMID27695075
PMCPMC5047441
OpenAlexW2529376134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.